Kriya Biosys Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 5 Year, 19 Days
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 7.50 M
- Revenue Growth 284.36%
- Profit Growth 1001.47%
- Ebitda 662.70%
- Net Worth 398.49%
- Total Assets 122.42%
About Kriya Biosys
Kriya Biosys Private Limited (KBPL) is a Private Limited Indian Non-Government Company incorporated in India on 14 January 2020 (Five years 19 days old ). Its registered office is in Salem, Tamil Nadu, India.
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.50 M.
The company has closed loans amounting to ₹7.50 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Company Details
-
Location
Salem, Tamil Nadu, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U01403TZ2020PTC033334
-
Company No.
033334
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
14 Jan 2020
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Coimbatore
Industry
Who are the key members and board of directors at Kriya Biosys?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kumarasamy Krishnaraj
|
Managing Director | 14-Jan-2020 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Sundararaman Abinayasundari
|
Director | 14-Jan-2020 | Current |
Financial Performance of Kriya Biosys.
Kriya Biosys Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 284.36% increase. The company also saw a substantial improvement in profitability, with a 1001.47% increase in profit. The company's net worth Soared by an impressive increase of 398.49%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kriya Biosys?
In 2022, Kriya Biosys had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Sira Corporation LlpKumarasamy Krishnaraj is a mutual person
Charges (Loans)
₹0
₹7.50 M
Charges Breakdown by Lending Institutions
- Others : 0.75 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Dec 2021 | Others | ₹7.50 M | Satisfied |
How Many Employees Work at Kriya Biosys?
Unlock and access historical data on people associated with Kriya Biosys, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kriya Biosys, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kriya Biosys's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.